drugset
drugset / Trial / NCT04896853

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

NCT04896853 ↗

Phase 1 Active not recruiting 9 enrolled NextCell Pharma Ab Karolinska Trial Alliance · collab
NaSingle-groupOpen-labelTreatment

Summary

To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.

Timeline

Start
2021-05-18
Primary completion
2027-03-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ProTrans Cell therapy 25 cells —
Subject ProTrans Cell therapy 100 cells —
Subject ProTrans Cell therapy 200 cells —

Indications

acute respiratory distress syndrome influenza pneumonia respiratory syncytial virus infectious disease